4 408

Cited 434 times in

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

DC FieldValueLanguage
dc.contributor.author권혁문-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author남정모-
dc.contributor.author신동호-
dc.contributor.author장양수-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author고영국-
dc.date.accessioned2014-12-19T17:16:59Z-
dc.date.available2014-12-19T17:16:59Z-
dc.date.issued2012-
dc.identifier.issn0735-1097-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/91120-
dc.description.abstractOBJECTIVES: The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. BACKGROUND: There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation. METHODS: We randomly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES+3-month DAPT, n=1,059) versus 12-month DAPT following the other DES implantation (standard therapy, n=1,058). We hypothesized that the E-ZES+3-month DAPT would be noninferior to the standard therapy for the primary composite endpoint (cardiovascular death, myocardial infarction, stent thrombosis, target\vessel revascularization, or bleeding) at 1 year. RESULTS: The primary endpoint occurred in 40 (4.7%) patients assigned to E-ZES+3-month DAPT compared with 41 (4.7%) patients assigned to the standard therapy (difference: 0.0%; 95% confidence interval [CI]: -2.5 to 2.5; p=0.84; p<0.001 for noninferiority). The composite rates of any death, myocardial infarction, or stent thrombosis were 0.8% and 1.3%, respectively (difference: -0.5%; 95% CI: -1.5 to 0.5; p=0.48). The rates of stent thrombosis were 0.2% and 0.3%, respectively (difference: -0.1%; 95% CI: -0.5 to 0.3; p=0.65) without its further occurrence after cessation of clopidogrel in the E-ZES+3-month DAPT group. The rates of target vessel revascularization were 3.9% and 3.7%, respectively (difference: 0.2%; 95% CI: -2.3 to 2.6; p=0.70). CONCLUSIONS: E-ZES+3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079).-
dc.description.statementOfResponsibilityopen-
dc.format.extent1340~1348-
dc.relation.isPartOfJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleA new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Preventive Medicine (예방의학)-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorDong-Ho Shin-
dc.contributor.googleauthorChung-Mo Nam-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorTae-Soo Kang-
dc.contributor.googleauthorByoung-Eun Park-
dc.contributor.googleauthorWoong-Chol Kang-
dc.contributor.googleauthorSeung-Hwan Lee-
dc.contributor.googleauthorJung-Han Yoon-
dc.contributor.googleauthorBum-Kee Hong-
dc.contributor.googleauthorHyuck-Moon Kwon-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.1016/j.jacc.2012.06.043-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00260-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA01264-
dc.contributor.localIdA02097-
dc.contributor.localIdA03448-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA00127-
dc.relation.journalcodeJ01770-
dc.identifier.eissn1558-3597-
dc.identifier.pmidantiplatelet therapy ; coronary artery disease ; drug-eluting stents-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S073510971203029X-
dc.subject.keywordantiplatelet therapy-
dc.subject.keywordcoronary artery disease-
dc.subject.keyworddrug-eluting stents-
dc.contributor.alternativeNameKwon, Hyuck Moon-
dc.contributor.alternativeNameKim, Byeong Keuk-
dc.contributor.alternativeNameKim, Jung Sun-
dc.contributor.alternativeNameNam, Jung Mo-
dc.contributor.alternativeNameShin, Dong Ho-
dc.contributor.alternativeNameJang, Yang Soo-
dc.contributor.alternativeNameChoi, Dong Hoon-
dc.contributor.alternativeNameHong, Myeong Ki-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthorKwon, Hyuck Moon-
dc.contributor.affiliatedAuthorKim, Byeong Keuk-
dc.contributor.affiliatedAuthorKim, Jung Sun-
dc.contributor.affiliatedAuthorNam, Jung Mo-
dc.contributor.affiliatedAuthorShin, Dong Ho-
dc.contributor.affiliatedAuthorJang, Yang Soo-
dc.contributor.affiliatedAuthorChoi, Dong Hoon-
dc.contributor.affiliatedAuthorHong, Myeong Ki-
dc.contributor.affiliatedAuthorKo, Young Guk-
dc.citation.volume60-
dc.citation.number15-
dc.citation.startPage1340-
dc.citation.endPage1348-
dc.identifier.bibliographicCitationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol.60(15) : 1340-1348, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.